Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
DP
DANCANN PHARMA A/S
aktivCVR 39426005AktieselskabRugvænget 5, 6823 AnsagerFremstilling af farmaceutiske præparater
- Latest accounts
- 2024
- Statement scope
- Consolidated
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2024
Revenue
DKK 7.4m
Revenue growth: 21.4%
Source details
Source: dk-regnskabsdata-live-39426005-1793864764363
Document: dk-regnskabsdata-39426005-AZbYIME44VR6ltiPaKV1-1
XBRL: fsa:Revenue
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx1
Unit: vDKK
Operating profit
DKK -7.2m
Latest period
Source details
Source: dk-regnskabsdata-live-39426005-1793864764363
Document: dk-regnskabsdata-39426005-AZbYIME44VR6ltiPaKV1-1
XBRL: fsa:ProfitLossFromOrdinaryOperatingActivities
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx1
Unit: vDKK
Net result
DKK -8.3m
Latest period
Source details
Source: dk-regnskabsdata-live-39426005-1793864764363
Document: dk-regnskabsdata-39426005-AZbYIME44VR6ltiPaKV1-1
XBRL: fsa:ProfitLoss
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx1
Unit: vDKK
Equity
DKK 14.6m
Equity ratio: 87.7%
Source details
Source: dk-regnskabsdata-live-39426005-1793864764363
Document: dk-regnskabsdata-39426005-AZbYIME44VR6ltiPaKV1-1
XBRL: fsa:Equity
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx72
Unit: vDKK
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2019 | DKK 0 | DKK -500k |
| 2020 | DKK 0 | DKK -4.3m |
| 2021 | DKK 874k | DKK -11.8m |
| 2022 | DKK 5.7m | DKK -16.1m |
| 2023 | DKK 6.1m | DKK -62.3m |
| 2024 | DKK 7.4m | DKK -8.3m |